Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of unusually large options trading activity on Wednesday. Traders acquired 1,002 put options on the stock. This is an increase of 1,791% compared to the average volume of 53 put options.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Tuesday, October 14th. Three analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $5.36.

Insider Transactions at Maravai LifeSciences

In related news, Director Gregory T. Lucier purchased 51,472 shares of the company’s stock in a transaction dated Friday, December 5th. The stock was acquired at an average cost of $3.70 per share, for a total transaction of $190,446.40. Following the completion of the transaction, the director directly owned 106,595 shares of the company’s stock, valued at approximately $394,401.50. This trade represents a 93.38% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Bernd Brust acquired 216,212 shares of Maravai LifeSciences stock in a transaction that occurred on Thursday, November 13th. The shares were bought at an average price of $3.25 per share, for a total transaction of $702,689.00. Following the transaction, the chief executive officer owned 466,771 shares of the company’s stock, valued at $1,517,005.75. This represents a 86.29% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 566,771 shares of company stock worth $1,880,244 over the last 90 days. 2.11% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Maravai LifeSciences

Several institutional investors have recently bought and sold shares of MRVI. Monaco Asset Management SAM boosted its stake in shares of Maravai LifeSciences by 315.0% in the third quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock valued at $10,494,000 after purchasing an additional 2,775,372 shares during the period. Philosophy Capital Management LLC acquired a new position in shares of Maravai LifeSciences in the first quarter worth $5,731,000. Tejara Capital Ltd increased its position in shares of Maravai LifeSciences by 257.8% during the second quarter. Tejara Capital Ltd now owns 1,941,449 shares of the company’s stock worth $4,679,000 after acquiring an additional 1,398,900 shares during the period. 12 West Capital Management LP raised its stake in shares of Maravai LifeSciences by 8.0% in the first quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company’s stock valued at $27,672,000 after acquiring an additional 930,000 shares in the last quarter. Finally, Deutsche Bank AG boosted its holdings in Maravai LifeSciences by 67.6% in the first quarter. Deutsche Bank AG now owns 2,072,239 shares of the company’s stock valued at $4,580,000 after purchasing an additional 835,600 shares during the period. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Price Performance

Maravai LifeSciences stock opened at $3.73 on Thursday. The company’s 50 day simple moving average is $3.36 and its 200-day simple moving average is $2.78. The company has a debt-to-equity ratio of 0.74, a quick ratio of 4.56 and a current ratio of 5.29. Maravai LifeSciences has a 1 year low of $1.66 and a 1 year high of $6.21. The company has a market capitalization of $953.80 million, a price-to-earnings ratio of -4.44 and a beta of 0.33.

Maravai LifeSciences (NASDAQ:MRVI) last posted its earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Maravai LifeSciences had a negative net margin of 62.88% and a negative return on equity of 22.42%. The company had revenue of $41.63 million during the quarter, compared to analyst estimates of $49.02 million. As a group, equities research analysts expect that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.